Nazartinib Uses, Dosage, Side Effects and more
Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).
| Trade Name | Nazartinib |
| Generic | Nazartinib |
| Nazartinib Other Names | Nazartinib |
| Type | |
| Formula | C26H31ClN6O2 |
| Weight | Average: 495.02 Monoisotopic: 494.219702 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
